Alnylam Pharmaceuticals, Inc. (ALNY)

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) is the global leader in RNA interference (RNAi) therapeutics, a revolutionary class of medicines that "silences" disease-causing genes. Led by CEO Yvonne Greenstreet, the company’s mission is to build a top-tier biotech company that delivers transformative medicines to patients with rare and common diseases. Alnylam envisions a future where its "Alnylam P5x25" strategy results in multiple blockbuster drug launches across cardiovascular, metabolic, and infectious diseases. As a pioneer in gene-silencing technology, ALNY stock is a primary vehicle for investors betting on the future of personalized medicine.

The business operations of Alnylam in late 2025 reached a pivotal stage with the announcement of a $250 million manufacturing expansion on December 17, 2025. This project will add a next-generation "Enzymatic Ligation" platform to its Massachusetts facility to meet the surging global demand for RNAi drugs. In December 2025, ALNY stock investors focused on the "HELIOS-B" Phase 3 data for Vutrisiran, which showed significant improvements in heart structure for ATTR-CM patients. The company’s core products include Onpattro, Givlaari, Oxlumo, and the high-growth Amvuttra. The future business strategy for ALNY stock involves the global launch of Zilebesiran for hypertension and expanding its pipeline into obesity and Type 2 diabetes. Throughout 2025, the company reported robust revenue growth, driven by the expanding market share of its subcutaneous rare-disease therapies. As RNAi becomes a mainstream treatment modality, the specialized manufacturing and R&D platform provided by ALNY stock has become an industry-leading asset, supporting the long-term growth case for the stock.

Alnylam Pharmaceuticals stock is listed on the Nasdaq under the ticker symbol ALNY. In late 2025, the ALNY stock price has seen strong momentum, recently trading near $245 as the market rewards its transition from a rare-disease specialist to a large-market biopharma powerhouse. Analysts monitoring the ALNY stock price highlight the company’s potential for multi-billion dollar peak sales from its cardiovascular pipeline. For those tracking the ALNY stock price today, the key catalysts include the FDA approval of Vutrisiran for ATTR-CM and new pipeline trial readouts. As a titan of the biotech world, ALNY stock remains a top selection for innovation-focused investors. The rising ALNY stock price reflects its status as a leader in genetic medicine.